Introduction {#s1}
============

Non-valvular atrial fibrillation (NVAF) is a major cause of ischemic stroke and systemic embolism and is consequently characterized by increased mortality and morbidity and higher costs of medical care [@pone.0091398-Dulli1], [@pone.0091398-Slot1]. Vitamin K antagonists (VKA), principally warfarin, have proved to be highly effective in preventing thromboembolic events in patients with paroxysmal, persistent, or permanent NVAF [@pone.0091398-Camm1]. In 29 randomized trials involving more than 28,000 patients, pooled according to meta-analytic methods, adjusted-dose warfarin reduced the risk of stroke by 64% compared to the control and by 37% compared to aspirin, but at the cost of an increased risk of bleeding [@pone.0091398-Camm1]. Furthermore, warfarin was associated with a 26% reduction in all-cause mortality, compared to no anticoagulation therapy, in randomized, controlled trials in patients with NVAF [@pone.0091398-Camm1].

New oral anticoagulants (NOAC), directly inhibiting thrombin or factor Xa, have recently been developed. Their wide therapeutic windows allow the use of fixed doses without any need for laboratory monitoring [@pone.0091398-Rupprecht1], [@pone.0091398-Garcia1]. These new drugs could potentially overcome the well-known limitations of VKA, such as slow onset of action, need for regular blood sampling to monitor the international normalized ratio (INR), narrow therapeutic windows, marked inter-individual variations in drug metabolism, and multiple drug-drug and drug-food interactions, all of which lead to an increased risk of bleeding [@pone.0091398-Fuster1], [@pone.0091398-Singer1], [@pone.0091398-Hylek1]. NOAC are associated with a reduced risk of stroke and systemic embolism as well as major bleeding, especially intracranial bleeding [@pone.0091398-Patel1], [@pone.0091398-Granger1], [@pone.0091398-Connolly1].

However, certain characteristics of patients with NVAF may modify the treatment effects of NOAC [@pone.0091398-Eikelboom1]. *Post hoc* analyses of trial data suggest that VKA-naïve patients have a different response when first treated with warfarin compared to those previously exposed to VKA, manifested by an increase in major bleeding [@pone.0091398-Olsson1], [@pone.0091398-Albers1], [@pone.0091398-Connolly2]. Moreover, an age \>75 years, comorbidities such as congestive heart failure, hypertension, diabetes mellitus, and previous stroke or transient ischemic attack, independently predict thromboembolism and are included in the CHADS2 score, the most reliably validated index for discriminating patients at higher risk of stroke [@pone.0091398-Gage1]. Several of these factors, namely advanced age, previous stroke and hypertension, are also associated with a risk of bleeding, as assessed by the HAS-BLED score [@pone.0091398-Camm2], [@pone.0091398-Lip1]. These comorbidities consequently affect the incidence of thromboembolic or bleeding events, or both, and may modify the benefits and harms of NOAC. Apart from the interrelationship between risk factors for stroke and bleeding, and the issue of VKA status (prior exposure or no prior exposure), the interpretation of subgroup analyses corresponding to these comorbidities is hampered in published trials by the small number of outcome events within each subgroup and the lack of power to detect interactions. At the same time, the multiple interaction tests performed in each trial engendered a risk of type 1 error, i.e. a false positive conclusion in favor of superiority of the treatment investigated over the comparator. The aim of the present meta-analysis was to evaluate the consistency of the reductions in stroke and bleeding risks in patients with NVAF irrespective of their comorbidities and VKA status.

Methods {#s2}
=======

Inclusion criteria {#s2a}
------------------

The meta-analysis was performed according to a prospectively developed protocol (available from the corresponding author on request), which pre-specified the research objective, search strategy, study eligibility criteria, and methods of data extraction and statistical analysis. All subgroup variables were defined before the analyses.

Studies were eligible for inclusion in the present meta-analysis if they were randomized, controlled trials conducted in patients with NVAF and reported results according to CHADS2 score, age, presence of heart failure and diabetes mellitus, estimated glomerular filtration rate, prior exposure to VKA, and previous stroke or transient ischemic attack (TIA). Patients in the control group had to have received VKA and patients in the treated group had to have received an oral Factor Xa or thrombin inhibitor. Double-blind and open-label trial designs with or without blinded outcome evaluation were eligible.

Data sources and searches {#s2b}
-------------------------

Medline (PubMed) and Embase were searched up to October 2012 using sensitive methods and employing the key words rivaroxaban, apixaban, betrixaban, edoxaban (DU-176b), eribaxaban, ximelagatran, dabigatran, LY 517717, darexaban (YM150), letaxaban, AZD0837, TTP889, RB006, MCC977 and TAK442 [@pone.0091398-Wong1], [@pone.0091398-Haynes1]. Search terms included combinations of free text and medical subject headings (MeSH or Emtree). The complete search strategies may be requested from the authors. The references cited by the studies, reviews and meta-analyses retrieved by searching PubMed and Embase were also examined. Unpublished and ongoing trials were sought in clinical trial registers, including those of the National Institute of Health, the National Research Register, Current Controlled Trials, Meta-Embol and Trials Central. We also searched the Internet using the keywords listed above, including websites dedicated to the dissemination of clinical trial results, such as TheHeart.org, and the websites of the European Medicines Agency and the US Food and Drug Administration.

Unpublished studies were included in the meta-analysis if their design had been previously published in detail and patient characteristics, follow-up and the main results had been presented at international congresses. No restrictions concerning non-English language or small population size were applied. All qualifying studies were assessed for adequate blinding of randomization, completeness of follow-up, and objectivity of the outcome assessment. Phase II trials and studies with short-term follow-ups (\<12 weeks) were excluded.

Outcomes {#s2c}
--------

The primary efficacy endpoint was the composite of stroke and systemic embolism. The primary safety endpoint was major bleeding (including both intracranial and extracranial bleeding), as defined by International Society on Thrombosis and Haemostasis [@pone.0091398-Schulman1].

Data extraction {#s2d}
---------------

Studies were selected and data extracted by two reviewers (JCL and CC) independently. The risk of bias was assessed by the Cochrane Collaboration\'s tool. The hazard ratio (or the relative risk) and its confidence interval were extracted for all subgroups and directly included in the pooled results [@pone.0091398-Parmar1]. Data regarding inclusion criteria, events by subgroup and treatment were abstracted for each individual study or *post hoc* analysis. The results obtained on the intention-to-treat population were used for the main efficacy analyses. The risk of bias was assessed by the Cochrane Collaboration\'s tool [@pone.0091398-Higgins1]. Disagreements were resolved by a third reviewer. If a trial compared two NOAC treatments to the reference treatment (VKA), the number of patients in the reference arm was divided by two so that each patient was included in the meta-analysis only once.

Statistical analysis {#s2e}
--------------------

The relative risks (RR) or hazard ratios were weighted by the inverse of their variance and combined using the logarithm of RR method according to fixed-effect and random-effect models by R [@pone.0091398-DerSimonian1], [@pone.0091398-Team1]. Interaction was systematically tested for all subgroups and was considered as significant at p \<0.05. The statistical heterogeneity between studies was assessed using Cochran\'s χ^2^ and I^2^ tests with a threshold of 0.10 [@pone.0091398-Higgins2]. In the event of heterogeneity, the results were pooled according to a random-effect model. Results were presented graphically, including the RR and corresponding 95% confidence intervals (95% CI).

Results {#s3}
=======

Literature search and study selection {#s3a}
-------------------------------------

We identified 1170 references through electronic searches and 17 references by manual searches and contact with experts ([Figure 1](#pone-0091398-g001){ref-type="fig"}). Among these, three studies (including 50,578 patients) were eligible for analysis [@pone.0091398-Patel1], [@pone.0091398-Granger1], [@pone.0091398-Connolly1], the results of which were reported in 11 publications in peer-reviewed journals, one international congress abstract, and one Food and Drug Administration (FDA) report [@pone.0091398-Easton1], [@pone.0091398-Lopes1], [@pone.0091398-Hohnloser1], [@pone.0091398-Darius1], [@pone.0091398-Oldgren1], [@pone.0091398-Ezekowitz1], [@pone.0091398-Diener1], [@pone.0091398-Food1], [@pone.0091398-Fox1], [@pone.0091398-Hankey1]. Patient characteristics, study designs and methodological features are shown in [Table 1](#pone-0091398-t001){ref-type="table"}. Patient inclusion criteria were based on various combinations of the known risk factors for thromboembolism included in the CHADS~2~ score and consequently the proportion of patients with a CHADS~2~ score \<2 differed greatly from study to study, ranging from 0 to 34%. The proportion of VKA-naïve patients varied from 37% to 50%. The risk of bias according to the Cochrane Collaboration\'s tool mainly reflected the high quality of the trials included ([Table 2](#pone-0091398-t002){ref-type="table"}). One prospective, randomized, open trial with a blind evaluation was included ([Tables 1](#pone-0091398-t001){ref-type="table"} and [2](#pone-0091398-t002){ref-type="table"}). Randomization was performed according to a computer-generated and centralized interactive voice-response system in all trials. One study stratified patients according to their prior VKA exposure and site of enrollment. In view of the few studies included, the source of heterogeneity was not explored.

![Flow chart for trial selection.](pone.0091398.g001){#pone-0091398-g001}

10.1371/journal.pone.0091398.t001

###### Characteristics of included studies.

![](pone.0091398.t001){#pone-0091398-t001-1}

  Trial, year                Design               NOAC class       Mean age (years) Men (%)   VKA- naïve patients   Patients with CHADS2 score \<2 (%)        ITT        Mean follow-up (months)   TTR (%)
  ----------------- ------------------------ -------------------- -------------------------- --------------------- ------------------------------------ --------------- ------------------------- ---------
  RE-LY, 2009           Phase III PROBE       Thrombin inhibitor            71.64%                   50%\*                         32%                   All outcomes             24.0               64
  ROCKET, 2011       Phase III Double-Blind    Anti- factor Xa†             73.60%                  37%\*\*                         0%                   Stroke and SE            23.2               55
  ARISTOTLE, 2011    Phase III Double-Blind    Anti- factor Xa†             70.65%                 43\*\*\*                        34%                   All outcomes             21.6               62

ITT: intention-to-treat analysis; PROBE: prospective, randomized, open trial with a blind evaluation; SE, systemic embolism; TTR: time during which the INR was in the therapeutic range. † Doses were reduced in patients with renal failure. VKA-naïve was defined as \* \<63 and \*\*\*\<31 days of lifetime VKA exposure, respectively, \*\* not defined in the trial protocol

10.1371/journal.pone.0091398.t002

###### Assessment of the risk of bias according to the Cochrane Collaboration\'s tool.

![](pone.0091398.t002){#pone-0091398-t002-2}

  ----------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- ---------------------
  RE-LY, 2009                    \+                         \+                               −                                    \+                           \+                      \+
  ROCKET, 2011                   \+                         \+                               \+                                   \+                           \+                      \+
  ARISTOTLE, 2011                \+                         \+                               \+                                   \+                           \+                      \+
                     Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting
  ----------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- ---------------------

+: Low risk of bias; −: high risk of bias

Direct thrombin inhibitors were assessed in one study and direct factor Xa inhibitors in two studies ([Table 1](#pone-0091398-t001){ref-type="table"}). Two trials used a reduced dose of the NOAC in patients with renal failure (apixaban 2.5 mg bid and rivaroxaban 15 mg, respectively) [@pone.0091398-Patel1], [@pone.0091398-Granger1], [@pone.0091398-Hori1]. All studies used adjusted-dose warfarin (target INR, 2.0 to 3.0) as the comparator. The proportion of time during which the INR was in the therapeutic range ranged from 55% to 64% ([Table 1](#pone-0091398-t001){ref-type="table"}). Renal function (GFR) was estimated by the Cockcroft-Gault method in all studies. The data according to subgroup are presented in the [Table 3](#pone-0091398-t003){ref-type="table"}.

10.1371/journal.pone.0091398.t003

###### Results of ARISTOTLE, RE-LY, and ROCKET-AF trials according to subgroup.

![](pone.0091398.t003){#pone-0091398-t003-3}

  Trial Name, Year          Group         Outcome            Heart failure (Yes/No)             Previous stroke-TIA (Yes/No)            CrCl (\<50 mL/min 50--80 mL/min \>80 mL/min)                       CHADS~2~ score                      Age (\>75 years/\<75 years)                 Diabetes mellitus (Yes/No)           Prior VKA useNaïve VKA patients
  ------------------ ------------------- --------- ------------------------------------------- ------------------------------ ---------------------------------------------------------------- --------------------------------------- ------------------------------------------- ------------------------------------------- ---------------------------------
  RELY, 2009            D 110 mg bid        SSE     HR 0.99 (0.69--1.42) HR 0.86 (0.67--1.09)         55/1195 128/4819         HR 0.89 (0.61--1.31) HR 0.91 (0.68--1.20) HR 0.83 (0.52--1.32)     0--1 42/19582 59/2088 \>2 82/1968     HR 0.88 (0.66--1.17) HR 0.93 (0.70--1.22)   HR 0.74 (0.51--1.08) HR 0.97 (0.76--1.23)           94/3011 89/3004
                                            MB      HR 0.83 (0.64--1.09) HR 0.79 (0.67--0.94)         65/1195 277/4819                           120/1151 154/2714 57/1899                      0--1 74/1958 2 121/2088 \>2 147/1968                204/2349 138/3666                           96/1177 246/4837                       166/3011 176/3004
                        D 150 mg bid        SSE     HR 0.75 (0.51--1.10) HR 0.61 (0.47--0.79)         51/1233 83/4843          HR 0.47 (0.30--0.74) HR 0.65 (0.47--0.88) HR 0.71 (0.44--1.15)    0--1 26/1958 2 35/2137 \>2 73/1981     HR 0.67 (0.49--0.90) HR 0.63 (0.46--0.86)   HR 0.62 (0.42--0.91) HR 0.66 (0.51--0.88)           73/3049 61/3026
                                            MB      HR 0.79 (0.60--1.03) HR 0.99 (0.84--1.16)        102/1233 297/4843                           123/1188 182/2777 80/1882                      0--1 84/1958 2 127/2137 \>2 188/1981                246/2466 153/3610                           117/1124 282/4952                      209/3049 190/3026
                             VKA            SSE                        \-                             65/1195 137/4827                                       \-                                  0--1 40/1859 2 60/2230 \>2 102/1933                       \-                                          \-                              105/2929 97/3093
                                            MB                         \-                             97/1195 324/4827                           112/1081 206/2806 94/1887                      0--1 105/1859 2 144/2230 \>2 172/1933               206/2423 215/3599                           102/1195 319/4827                      216/2929 205/3093
                      R 15 or 20 mg od      SSE                 160/4438 109/2642                     187/3892 82/3189                            77/1490 126/3298 65/2285                              2 30/924 \>2 239/6156                       125/3082 144/3999                           95/2851 174/4230                       168/4413 101/2668
  ROCKET, 2010                              MB                  106/4428 83/2632                      136/3881 53/3180                            50/1485 91/3290 47/2278                               2 21/922 \>2 168/6138                       82/3073 107/3988                            70/2842 119/4219                       114/4401 75/2660
                             VKA            SSE                 172/4413 134/2676                    190/3875 116/3215                            86/1459 151/3400 68/2222                              2 36/933 \>2 270/6155                       154/3082 152/4008                           114/2796 192/4294                      175/4440 131/2650
                                            MB                  141/4409102/2672                      151/386992/3213                             60/1456 128/3396 54/2221                              2 24/931\>2 219/6149                        124/3077119/4005                             94/2793149/4289                       140/4437103/2645
                      A 2.5 or 5 mg bid     SSE                 70/3235 142/5885                      73/1748 139/7372                            54/1502 87/3817 70/3761                        0--1 44/3100 2 74/3262 \>2 94/2758                 79/2850 133/6270                            57/2284 155/6836                       102/5208 110/3912
  ARISTOTLE, 2011                           MB                  87/3235 240/5885                      77/1748 250/7372                            73/1502 157/3817 96/3761                      0--1 76/3100 2 125/3262 \>2 126/2758                151/2850 176/6270                           112/2284 215/6836                      185/5208 142/3912
                             VKA            SSE                 79/3216 186/5865                      98/1790 167/7291                            69/1515 116/3770 79/3757                       0--1 51/3083 2 82/3254 \>2 132/2744                109/2828 156/6253                           75/2263 190/6818                       138/5193 127/3888
                                            MB                  137/3216 325/5865                    106/1790 356/7291                           142/1515 199/3770 119/3757                     0--1 126/3083 2 163/3254 \>2 173/2744               224/2828 238/6253                           114/2263 348/6818                      274/5193 188/3888

A: apixaban; Bid: twice daily; D: dabigatran; HR: hazard ratio; MB: major bleeding; NR: not reported; od: once daily; R: rivaroxaban; SE: systemic embolism; SSE: stroke and/or systemic embolism; TIA: transient ischemic attack; VKA: vitamin K antagonist.

Stroke/systemic embolism and major bleeding risk reduction {#s3b}
----------------------------------------------------------

### Age and renal insufficiency {#s3b1}

Treatment benefit with regard to SSE risk reduction favored NOAC compared to VKA in both patients aged over 75 years and younger patients ([Figures 2](#pone-0091398-g002){ref-type="fig"} and [3](#pone-0091398-g003){ref-type="fig"}). The benefit remained in favor of NOAC with regard to major bleeding, even though the reduction in risk was lower in elderly patients (RR = 0.86 \[0.65--1.14\]) than in younger patients (RR = 0.73 \[0.64--0.83\], p interaction = 0.30) ([Figures 2](#pone-0091398-g002){ref-type="fig"} and [4](#pone-0091398-g004){ref-type="fig"}). Similar results were observed in patients with normal renal function and those with moderate or severe renal impairment, the reductions in SSE and MB being similar in the two subgroups. No interaction was found between these two subgroups.

![Relative risk of stroke and systemic embolism and major bleeding reduction according to age, comorbidities and VKA status.](pone.0091398.g002){#pone-0091398-g002}

![Detailed forest plot of stroke and systemic embolism according to (A) age, (B) renal function, (C) prior VKA exposure, (D) CHADS~2~ score, (E) heart failure, (F) prior stroke or transient ischemic attack, (G) diabetes mellitus.](pone.0091398.g003){#pone-0091398-g003}

![Detailed forest plot of major bleeding according to (A) age, (B) renal function, (C) prior VKA exposure, (D) CHADS~2~ score, (E) heart failure, (F) prior stroke or transient ischemic attack, (G) diabetes mellitus.](pone.0091398.g004){#pone-0091398-g004}

### Previous exposure to VKA {#s3b2}

NOAC were superior to VKA irrespective of subgroup, reductions in SSE (Figure S2 and S3) and MB ([Figures 2](#pone-0091398-g002){ref-type="fig"} and [4](#pone-0091398-g004){ref-type="fig"}) being seen in both VKA-naïve patients (RR = 0.80 \[0.70--0.92\] and RR = 0.84 \[0.76--0.94\], respectively) and those previously exposed to VKA (RR = 0.83 \[0.73--0.94\] and RR = 0.78 \[0.68--0.91\], respectively), with no interaction.

### CHADS~2~ score {#s3b3}

The treatment effect of NOAC in terms of SSE reduction was similar (p =  0.92) irrespective of the CHADS~2~ score ([Figures 2](#pone-0091398-g002){ref-type="fig"} and [3](#pone-0091398-g003){ref-type="fig"}). The risk of thromboembolism, as defined by the CHADS~2~ score, significantly modified the effect of NOAC on MB reduction (p interaction = 0.01), a greater effect being evident in patients with CHADS~2~ scores of 0--1 (RR = 0.67 \[0.57--0.79\]) than in those with CHADS~2~ scores ≥2 (RR = 0.85 \[0.74--0.98\]) ([Figures 2](#pone-0091398-g002){ref-type="fig"} and [4](#pone-0091398-g004){ref-type="fig"}).

### Comorbidities included in the CHADS~2~ score: heart failure, prior stroke/transient ischemic attack, and diabetes mellitus {#s3b4}

A trend towards interaction with heart failure (p = 0.08) was observed with respect to SSE reduction, this being greater in patients not presenting heart failure (RR = 0.76 \[0.67--0.86\]) than in those with heart failure (RR = 0.90 \[0.78--1.04\]) ([Figures 2](#pone-0091398-g002){ref-type="fig"} and [3](#pone-0091398-g003){ref-type="fig"}). As regards MB, the test for interaction showed a non-significant trend (p = 0.06) towards a difference between patients with (RR = 0.97 \[0.79--1.18\]) and without (RR = 0.76 \[0.65--0.88\]) diabetes mellitus ([Figures 2](#pone-0091398-g002){ref-type="fig"} and [4](#pone-0091398-g004){ref-type="fig"}). No interaction was detected for any other comorbidity considered.

Discussion {#s4}
==========

The goal of this study was to assess the consistency of the benefit-risk balance of NOAC in patients with NVAF irrespective of their characteristics. Overall, our meta-analysis showed a similar treatment effect of NOAC in almost all the subgroups encountered in clinical practice, with no qualitative interaction in terms of SSE or MB reduction, i.e. no reversal of treatment effect leading to an increase of events with NOAC compared to warfarin. However, there was a significant quantitative interaction, expressed by a difference in magnitude of the treatment effect according to subgroup, the effect of NOAC with regard to MB reduction being smaller in patients with a high risk of SSE (CHADS~2~ score ≥2). There was also a strong trend towards interaction with diabetes mellitus in patients with a CHADS~2~ score ≥2. It is conceivable that co-prescription of antiplatelet drugs, more frequent in patients with a CHADS~2~ score ≥2 or diabetes mellitus, might explain an increased incidence of bleeding events but *post hoc* analysis of the RE-LY trial did not indicate an interaction with co-administration of clopidogrel or aspirin in terms of MB [@pone.0091398-Dans1]. Some authors have questioned the repercussions of the variable proportion of patients with a high CHADS2 score across phase III trials [@pone.0091398-Ahrens1], [@pone.0091398-Harenberg1]. In particular, the population included in the ROCKET-AF trial differed from those of ARISTOTLE and RE-LY in that it comprised a higher proportion of patients with comorbidities. In addition, heart failure may modify the benefit of NOACs with respect to SEE reduction, but the magnitude of the interaction did not permit to draw firm conclusions. Our results tend to corroborate this concern and call for careful interpretation of indirect comparisons of the results of trials assessing NOAC [@pone.0091398-Harenberg1].

In published trials, the safety and efficacy profiles of NOAC were not worse than those of VKA, irrespective of patient age and prior exposure to VKA [@pone.0091398-Connolly2], [@pone.0091398-Ezekowitz1]. Moreover, all subgroups derived a significant benefit from these new drugs in terms of reductions in MB and/or SSE. NOAC reduced major bleeding in all subgroups at risk of this iatrogenic event, such as those aged ≥75 years, those having experienced a stroke in the past, those with a high CHADS2 score and those presenting renal impairment [@pone.0091398-Lip1], [@pone.0091398-Oldgren1]. The two subgroups at greatest risk of NOAC accumulation, i.e. elderly patients and those with renal failure, both showed a higher incidence of bleeding and thromboembolic events [@pone.0091398-Eikelboom2]. However, both these subgroups nevertheless derived benefit from NOAC in terms of diminished SSE risk, with no signal indicating an increase in MB, except in the case of dabigatran 150 mg, which was associated with a trend towards an increased risk of MB compared to VKA. In addition, comparison of both dabigratran doses with warfarin revealed a significant statistical interaction between treatment and risk of major bleeds in elderly patients [@pone.0091398-Food1]. In patients with renal failure, subgroup analysis showed a heterogeneity of treatment effect, related to a relative increase in bleeding events with dabigatran compared to rivaroxaban and apixaban. We postulated that the percentage renal clearances of 80%, 33% and 25% respectively, in the three treatment groups, might have led to an increased bleeding risk with dabigatran due to drug accumulation. Overall, the reduction in the rate of SSE observed with NOAC versus VKA was similar in patients at increased risk of thromboembolism events, such as those having experienced a prior TIA/stroke, those presenting diabetes mellitus or heart failure, and those aged ≥75 years [@pone.0091398-Lip2]. The results were same whether or not the patients had previously been exposed to VKA.

Our study suffers from several limitations. First, it comprised a meta-analysis of subgroups. However, most of these subgroups were well defined and included in the stratification scheme for randomization in each study. As discussed above, it is likely that the the studies included in this meta-analysis were not powered to reach significance for many outcomes in subgroups such as those comprising patients with a CHADS2 score \<2, those having previously experienced a TIA or stroke or those with a GFR\<50 mL/min, due to the small population sizes. Second, we found significant heterogeneity for eight subgroups, but unfortunately, could not analyze its possible causes in view of the small number of trials included. Heterogeneity was mainly observed with respect to MB, a composite outcome encompassing both intracranial and extracranial bleeding. Whereas the disparity between the effect of NOAC and that of VKA followed the same trend in all trials with respect to SSE, the results for MB diverged, the risk of gastrointestinal bleeding being greater with rivaroxaban and with dabigatran at 150 mg than with VKA [@pone.0091398-Patel1], [@pone.0091398-Connolly1], [@pone.0091398-Holster1]. Besides the interaction between CHADS2 score and treatment effect, the intrinsic pharmacodynamic properties of the different drugs, e.g. their extent of renal excretion, might explain such differences in the reduction of extracranial bleeding. Finally, we could not exclude inflation of the type 1 error due to the multiple tests performed. For this reason, we choose a conservative threshold of significance (p \<0.05) to limit the risk of false positive results despite the lack of power of the interaction test [@pone.0091398-Altman1].

In conclusion, NOAC appear to be more effective and safer than VKA in reducing SSE or MB irrespective of patient comorbidities. The risk of thromboembolism, as evaluated by the CHADS2 score, and to a lesser extent the presence of diabetes mellitus and heart failure, modified the treatment effect of NOA without complete loss of benefit in terms of MB reduction. Other comorbidities, especially moderate renal impairment or prior VKA use, were not associated with significant differences in treatment effect with regard to either bleeding or ischemic risk reduction. Overall, these new drugs were beneficial for all patient subgroups in the absence of any contraindication.
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